These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9044517)

  • 21. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intracavernous injection of papaverine, phentolamine and phenoxybenzamine.
    Pettirossi O; Serenelli G
    Acta Urol Belg; 1988; 56(2):211-9. PubMed ID: 3400527
    [No Abstract]   [Full Text] [Related]  

  • 24. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects.
    Shamloul R; Atteya A; Elnashaar A; Gadallah A; Zohdy W; Abdelsalam W
    J Sex Med; 2005 Jan; 2(1):117-20. PubMed ID: 16422914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance to longterm vasoactive intracavernous therapy.
    Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G
    Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence.
    Gasser TC; Roach RM; Larsen EH; Madsen PO; Bruskewitz RC
    J Urol; 1987 Apr; 137(4):678-80. PubMed ID: 3550149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of vardenafil versus papaverine in penile Doppler ultrasonography.
    Ardicoglu A; Kocakoc E; Tuygun UO; Bozgeyik Z; Orhan I
    Urol Int; 2005; 75(1):75-9. PubMed ID: 16037713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury.
    Bodner DR; Lindan R; Leffler E; Kursh ED; Resnick MI
    J Urol; 1987 Aug; 138(2):310-1. PubMed ID: 3599245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of erectile dysfunction using papaverine--2 1/2 years' experience].
    Schnyder von Wartensee M; Sieber A; Studer UE
    Schweiz Med Wochenschr; 1988 Jul; 118(30):1099-103. PubMed ID: 3175561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-invasive management of impotence with transcutaneous nitroglycerin.
    Meyhoff HH; Rosenkilde P; Bødker A
    Br J Urol; 1992 Jan; 69(1):88-90. PubMed ID: 1737261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury.
    Sidi AA; Cameron JS; Dykstra DD; Reinberg Y; Lange PH
    J Urol; 1987 Sep; 138(3):539-42. PubMed ID: 2442418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcutaneous nitroglycerine in the treatment of erectile dysfunction: a placebo controlled clinical trial.
    Gramkow J; Lendorf A; Zhu J; Meyhoff HH
    Int J Impot Res; 1999 Feb; 11(1):35-9. PubMed ID: 10098952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of intracavernous injection of vasoactive medications for the restoration of erection in spinal cord injured males: a three year follow up.
    Bodner DR; Leffler B; Frost F
    Paraplegia; 1992 Feb; 30(2):118-20. PubMed ID: 1589286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
    Afferi L; Pannek J; Louis Burnett A; Razaname C; Tzanoulinou S; Bobela W; da Silva RAF; Sturny M; Stergiopulos N; Cornelius J; Moschini M; Iselin C; Salonia A; Mattei A; Mordasini L
    Andrology; 2020 Nov; 8(6):1660-1673. PubMed ID: 32741129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
    Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
    Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery.
    Stief CG; Wetterauer U
    J Urol; 1988 Dec; 140(6):1415-6. PubMed ID: 3193506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papaverine topical gel for treatment of erectile dysfunction.
    Kim ED; el-Rashidy R; McVary KT
    J Urol; 1995 Feb; 153(2):361-5. PubMed ID: 7815584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.